[Intensive atorvastatin therapy in patients with acute myocardial infarction]
Lan-feng Wang1, Zhu-qin Li, Qing Tang
1Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China. bluetime_20@163.com
Insights
High-dose atorvastatin (40 mg daily) effectively reduces LDL cholesterol and C-reactive protein in acute myocardial infarction patients, with manageable liver enzyme elevations. This intensive therapy is safe and beneficial for AMI recovery.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) is a leading cause of cardiovascular mortality.
- Statins, particularly atorvastatin, are crucial in managing cardiovascular risk post-AMI.
- Optimizing statin dosage is essential for maximizing therapeutic benefits.
Purpose of the Study:
- To evaluate the safety and efficacy of high-dose (40 mg daily) atorvastatin in patients following an acute myocardial infarction.
- To assess the impact of intensive atorvastatin therapy on lipid profiles and inflammatory markers.
Main Methods:
- A cohort of 1102 patients with AMI received atorvastatin 40 mg daily within 24 hours of admission.
- Dosage was adjusted to 20 mg daily for patients with low LDL-C or elevated liver enzymes at discharge.
- Lipid profiles, high-sensitivity C-reactive protein (hs-CRP), and liver enzymes were monitored at admission, discharge, and 3 months post-discharge.
Main Results:
- Atorvastatin significantly reduced LDL-C, HDL-C (initially), TC, and apoB levels throughout the study period (P < 0.05).
- High-sensitivity C-reactive protein (hs-CRP) levels demonstrated a significant decrease from admission to 3 months post-discharge (P < 0.05).
- Transient elevations in ALT and AST were observed in 11.25% and 2.40% of patients, respectively, with most normalizing by 3 months.
Conclusions:
- Intensive atorvastatin therapy (40 mg daily) is a safe and effective treatment strategy for patients with acute myocardial infarction.
- The regimen leads to significant improvements in lipid profiles and inflammatory markers, contributing to patient recovery.
- Monitoring for liver enzyme elevations is recommended, as transient increases are manageable.
Objective:
To assess the safety and efficacy of 40 mg daily atorvastatin in patients with acute myocardial infarction.
Methods:
A total of 1102 patients with AMI admitted to our hospital from 2003 to 2007 were assigned to atorvastatin 40 mg daily within 24 hours of hospitalization and continued till 3 months post discharge. Patients with LDL-C < 2.0 mmol/L or increased liver enzyme level (3 times higher than normal) at discharge received atorvastatin 20 mg daily. Lipid profiles, high-sensitivity C-reactive protein, liver enzyme level were measured at admission, hospital discharge and 3 months after discharge.
Results:
(1)The mean hospitalization duration was (10.17 +/- 1.83) days. LDL-C was continuously decreased [(3.24 +/- 1.04) mmol/L at admission, (2.27 +/- 2.00) mmol/L at discharge and (1.48 +/- 0.78) mmol/L at 3 months after discharge, all P < 0.05]. HDL-C decreased from (1.45 +/- 0.38) mmol/L to (1.20 +/- 0.30) mmol/L at hospital discharge, then increased to (1.65 +/- 1.79) mmol/L at 3 months after hospital discharge (all P < 0.05). TC and apoB were also significantly decreased from admission to discharge (all P < 0.05). (2) high-sensitivity C-reactive protein level significantly decreased from admission to hospital discharge and at 1 months after hospital discharge [(49.71 +/- 50.46) mg/L vs. (8.80 +/- 17.66) mg/L vs. (2.61 +/- 2.30) mg/L, all P < 0.05]. (3) Increased ALT > 120 U/L (3 times higher than normal) were found in 127(11.25%), AST > 120 U/L were found in 26(2.40%) patients at discharge. There were still 4 patients with increased ALT (> 120 U/L) at 1 months after discharge and all returned to normal at 3 months after discharge.
Conclusion:
Intensive atorvastatin therapy with a dose of 40 mg daily is safe and effective for patients with AMI.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Angina IV: Management
Myocarditis III: Medical Management
